ELEVATION ONCOLOGY INC (ELEV)
US28623U1016 - Common Stock
ELEVATION ONCOLOGY INC
NASDAQ:ELEV (12/20/2024, 8:06:57 PM)
After market: 0.608 +0.03 (+4.83%)0.58
-0.05 (-7.3%)
Company Profile
Elevation Oncology, Inc. is a precision oncology company, which engages in the development of targeted therapeutics for the treatment of cancer in genomically-defined patient populations. The company is headquartered in Boston, Massachusetts and currently employs 29 full-time employees. The company went IPO on 2021-06-25. The firm is focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. Its lead product candidate, EO-3021 is an antibody-drug conjugate (ADC) designed to target Claudin 18.2, which can selectively deliver a cytotoxic payload directly to cancer cells expressing Claudin 18.2. EO-3021 consists of a fully human immunoglobulin G1 (IgG1) mAb that targets Claudin 18.2 and is site-specifically conjugated to the monomethyl auristatin E (MMAE) payload via a cleavable linker with a drug-to-antibody ratio (DAR) of 2. EO-3021 is designed to bind to Claudin 18.2 on the cell surface and is internalized, upon which the linker is cleaved in the lysosome to release the MMAE payload, a potent anti-mitotic agent. Its second program is an ADC designed to target HER3, which is overexpressed across solid tumors.
Company Info
ELEVATION ONCOLOGY INC
101 Federal Street, Suite 1900
Boston MASSACHUSETTS
P: 17163711125
CEO: Shawn Leland
Employees: 29
Website: https://elevationoncology.com/
ELEV News
10 days ago - Elevation OncologyElevation Oncology Expands Pipeline with Nomination of EO-1022, a HER3 ADC for the Treatment of HER3-expressing Solid Tumors/PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies...
17 days ago - Elevation OncologyElevation Oncology Presents Preclinical Proof-of-Concept Data Supporting Combination Potential of EO-3021 with VEGFR2 or PD-1 Inhibitors at ESMO Immuno-Oncology Annual Congress 2024/PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies...
26 days ago - Elevation OncologyElevation Oncology to Present at the Piper Sandler 36th Annual Healthcare Conference/PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies...
2 months ago - Elevation OncologyElevation Oncology Reports Third Quarter 2024 Financial Results and Highlights Recent Business Achievements-- Promising initial Phase 1 data of EO-3021 reported in August highlighting 42.8% confirmed ORR observed in Claudin 18.2-enriched subset of gastric and GEJ...
3 months ago - Elevation OncologyElevation Oncology Receives Fast Track Designation from the FDA for EO-3021 for the Treatment of Adult Patients with Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer Expressing Claudin 18.2/PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies...
4 months ago - Elevation OncologyElevation Oncology to Present at the H.C. Wainwright 26th Annual Global Investment Conference/PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies...
ELEV Twits
Here you can normally see the latest stock twits on ELEV, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
